News Related to OCU410ST

Related coverage linked through entity extraction aliases.

Ocugen Completes Enrollment in Pivotal Stargardt Disease Gene Therapy Study

Apr 03, 2026

Ocugen has completed enrollment and dosing in its phase II/III GARDian3 study for OCU410ST gene therapy targeting Stargardt disease. The study includes 63 patients and aims to address over 1,200 ABCA4 gene mutations with a single treatment. Interim data is expected in Q3 2026, with a BLA submission targeted for mid-2027.

Ocugen Reports Phase 2 Data for Geographic Atrophy Gene Therapy OCU410

Mar 24, 2026

Ocugen reported Phase 2 data for its geographic atrophy gene therapy OCU410 showing 31% lesion growth reduction versus control. The company plans Phase 3 initiation in Q3 2026 and maintains its goal of three BLA filings in three years. Shares fell 11.48% following the data release which trailed earlier interim results.